130 related articles for article (PubMed ID: 26267136)
1. The Mechanism by which 146-N-Glycan Affects the Active Site of Neuraminidase.
Liu P; Wang Z; Zhang L; Li D; Lin J
PLoS One; 2015; 10(8):e0135487. PubMed ID: 26267136
[TBL] [Abstract][Full Text] [Related]
2. Glycan binding and specificity of viral influenza neuraminidases by classical molecular dynamics and replica exchange molecular dynamics simulations.
Phanich J; Threeracheep S; Kungwan N; Rungrotmongkol T; Hannongbua S
J Biomol Struct Dyn; 2019 Aug; 37(13):3354-3365. PubMed ID: 30126341
[TBL] [Abstract][Full Text] [Related]
3. Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase.
Kar P; Knecht V
J Phys Chem B; 2012 May; 116(21):6137-49. PubMed ID: 22553951
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6.
Venkatramani L; Johnson ES; Kolavi G; Air GM; Brouillette WJ; Mooers BH
BMC Struct Biol; 2012 May; 12():7. PubMed ID: 22559154
[TBL] [Abstract][Full Text] [Related]
5. MD simulation of the interaction between sialoglycans and the second sialic acid binding site of influenza A virus N1 neuraminidase.
Elli S; Gambacorta N; Rudd TR; Matrosovich M; Guerrini M
Biochem J; 2021 Jan; 478(2):423-441. PubMed ID: 33410905
[TBL] [Abstract][Full Text] [Related]
6. Multiscale Simulations Examining Glycan Shield Effects on Drug Binding to Influenza Neuraminidase.
Seitz C; Casalino L; Konecny R; Huber G; Amaro RE; McCammon JA
Biophys J; 2020 Dec; 119(11):2275-2289. PubMed ID: 33130120
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of 150-cavity formation in influenza neuraminidase.
Amaro RE; Swift RV; Votapka L; Li WW; Walker RC; Bush RM
Nat Commun; 2011 Jul; 2():388. PubMed ID: 21750542
[TBL] [Abstract][Full Text] [Related]
8. Plasticity of 150-loop in influenza neuraminidase explored by Hamiltonian replica exchange molecular dynamics simulations.
Han N; Mu Y
PLoS One; 2013; 8(4):e60995. PubMed ID: 23593372
[TBL] [Abstract][Full Text] [Related]
9. The 340-cavity in neuraminidase provides new opportunities for influenza drug development: A molecular dynamics simulation study.
Han N; Mu Y; Miao H; Yang Y; Wu Q; Li J; Ding J; Xu B; Huang Z
Biochem Biophys Res Commun; 2016 Jan; 470(1):130-136. PubMed ID: 26768362
[TBL] [Abstract][Full Text] [Related]
10. Plasticity of the 340-Loop in Influenza Neuraminidase Offers New Insight for Antiviral Drug Development.
Han N; Ng JTY; Li Y; Mu Y; Huang Z
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781779
[TBL] [Abstract][Full Text] [Related]
11. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
Woods CJ; Malaisree M; Pattarapongdilok N; Sompornpisut P; Hannongbua S; Mulholland AJ
Biochemistry; 2012 May; 51(21):4364-75. PubMed ID: 22574858
[TBL] [Abstract][Full Text] [Related]
12. The influence of 150-cavity binders on the dynamics of influenza A neuraminidases as revealed by molecular dynamics simulations and combined clustering.
Greenway KT; LeGresley EB; Pinto BM
PLoS One; 2013; 8(3):e59873. PubMed ID: 23544106
[TBL] [Abstract][Full Text] [Related]
13. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
14. Active 1918 pandemic flu viral neuraminidase has distinct N-glycan profile and is resistant to trypsin digestion.
Wu ZL; Ethen C; Hickey GE; Jiang W
Biochem Biophys Res Commun; 2009 Feb; 379(3):749-53. PubMed ID: 19133226
[TBL] [Abstract][Full Text] [Related]
15. Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation of drug unbinding and rebinding in simulation.
Woods CJ; Malaisree M; Long B; McIntosh-Smith S; Mulholland AJ
Biochemistry; 2013 Nov; 52(45):8150-64. PubMed ID: 24128064
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulation of Autotaxin: roles of the nuclease-like domain and the glycan modification.
Koyama M; Nishimasu H; Ishitani R; Nureki O
J Phys Chem B; 2012 Oct; 116(39):11798-808. PubMed ID: 22967301
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based inhibitors to probe transitional states of glycoside hydrolases.
Hinou H; Kurogochi M; Nishimura S
Methods Enzymol; 2006; 415():202-12. PubMed ID: 17116476
[TBL] [Abstract][Full Text] [Related]
18. Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1.
Li Y; Zhou B; Wang R
J Mol Graph Model; 2009 Oct; 28(3):203-19. PubMed ID: 19656699
[TBL] [Abstract][Full Text] [Related]
19. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
Pan P; Li L; Li Y; Li D; Hou T
Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835
[TBL] [Abstract][Full Text] [Related]
20. How hydrophobicity and the glycosylation site of glycans affect protein folding and stability: a molecular dynamics simulation.
Lu D; Yang C; Liu Z
J Phys Chem B; 2012 Jan; 116(1):390-400. PubMed ID: 22118044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
